Aerie Pharmaceuticals Inc (AERI) Files Form 4 Insider Buying : Gerald D. Cagle Buys 4,646 Shares

Aerie Pharmaceuticals Inc (AERI): Gerald D. Cagle , director of Aerie Pharmaceuticals Inc purchased 4,646 shares on Feb 4, 2015. The Insider buying transaction was reported by the company on Apr 26, 2016 to the Securities and Exchange Commission. The shares were purchased at $18.24 per share for a total value of $84,765.64 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 26, 2016, Gerald D. Cagle (director) purchased 4,646 shares at $18.24 per share price.On Apr 16, 2015, Anand Mehra (director) sold 425,000 shares at $33.76 per share price.

Aerie Pharmaceuticals Inc: On Friday, Apr 22, 2016 heightened volatility was witnessed in Aerie Pharmaceuticals Inc which led to swings in the share price. The shares opened for trading at $15.97 and hit $16.57 on the upside , eventually ending the session at $16.56, with a gain of 3.50% or 0.56 points. The heightened volatility saw the trading volume jump to 3,25,584 shares. The 52-week high of the share price is $35.6 and the company has a market cap of $439 M . The 52-week low of the share price is at $8.835.

Aerie Pharmaceuticals Inc Money Flow Index Chart

Aerie Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates triple-action Rhopressa and quadruple-action Roclatan are once-daily eye drops. The Company’s product candidate once-daily quadruple-action Roclatan is a single drop fixed-dose combination of Rhopressa and latanoprost. Rhopressa inhibits Rho Kinase (ROCK) and the norepinephrine transporter (NET) which are both biochemical targets for lowering intraocular pressure (IOP). The Company’s Rhopressa product candidate was in Phase III stage of development. The Company has completed the Roclatan Phase IIb clinical trial. The Company is also in the preclinical development stage with AR-13533 its second-generation ROCK/NET inhibitor.

Leave a Reply

Aerie Pharmaceuticals Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Aerie Pharmaceuticals Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.